An assay of serum digoxin and other cardiac glycosides by displacement of 3H-ouabain from Na-K ATPase is described. It is rapidly set up by any laboratory with a liquid scintillation counter. It can also assay digitalis leaf, digitoxin, and gitalin (Gitaligin), and has uncovered unsuspected administration of them.
routinely performed, 5 ml of serum is extracted with 30 Circulation, Volume XLV, January 1972 chromatography of this material in chloroform/ methanol/water, 65/30/5, v/v/v, on silica gel G plates gave a single distinct peak of radioactivity which migrated along with authentic reference unlabeled ouabain. In addition, the silica gel column chromatography procedure described later also gave a single peak of radioactivity (see Results, Column Procedure). Tritiated digoxin (3.2 Ci/mmole) and digitoxin (1 Ci/mmole) were obtained in 100% ethanol.tt All other chemicals were reagent grade or better. Liquid reagents and solutionls were kept in automatic dispensers.+< All microliter pipetting was done with Eppendorf pipets*** (rendered leak-free each morning), except for the dispensing of the enzyme and isotope solution in 20-,ul fractions, which was done with a Hamilton no. 1001 syringe fitted into a PB600 Hamilton repeater. The enzyme and isotope solution could be more accurately pipetted with the Eppendorf pipets by "reverse pipetting." The sample was taken up after fully depressing the plunger to the second stop, and the stated volume of the pipet was then dispensed by depressing the plunger only to the first stop. Serum was extracted in Pyrex no. 8124 40-ml conical centrifuge tubes. Chloroform was evaporated on a Buchler evapomixer. Final assay of samples employed plastic centrifuge tubes § § (0.4 ml). Incubation of the sample was done in a 37, 45, or 50°C water bath maintained within -+-1°C. Incubation was terminated by centrifugation in a Spinco model 152 bench-top microcentrifuge.
Counting of tritium was done on liquid scintillation counters with tritium efficiency of either 20 or 36%, and employed polyethylene scintillation vials and 10 ml of scintillant, which consisted of 21 Figure 2 Time course of 3H-ouabain uptake by the enzyme preparation as shown by decreasing counts of free 3H-ouabain. Absence of ATP or presence of 5 mM K inhibits uptake. CPM -counts per minute.
The homogenizer was rinsed with 5 ml of 0.25 1!i sucrose, and the combined samples were then centrifuged at 4°C for 20 min at 2600 X g (tip).
The supernatant was discarded. The pellet was again transferred to the homogenizer. Fifteen ml of 5 mmr TRIS-HCI, pH 7.2, was added, and the sample homogenized for 1 min at 0°C. The homogenate was transferred to the centrifuge tube along with another rinse of the homogenizer using 5 ml of 5 mxi TRIS-HCI, pH 7.2. It was again centrifuged at 2600 x g for 20 min and the supernatant discarded. This procedure was repeated three times so that the pellet received a total of four washes with 5 mm TRIS-HCI, pH 7.2.
The pellet vas then taken up to a volume of 50 ml with 5 mms TRIS-HCI, pH 7.2. To this was added 50 ml of a solution containing 10 mmi CaCl2 and 5 mms TRIS-HCI, pH 7.2. This homogenate was gently mixed, incubated for 1 hour at 300C, and then centrifuged at 4°C for 20 min at 2600 x g.
The supernatant was discarded and the pellet taken up with 50 ml of 0.6 M sucrose. The volume was then adjusted to 100 ml with water to give a final concentration of 0.3 mI sucrose. The sample was then centrifuged very gently at 4°C for 5 min at only 220 x g (tip). The milky supei-natant was then dialyzed overnight against 2 liters of 5 mm TRIS-HCI, pH 8.0, at 4°C, in dialysis tubing (Van Waters and Rogers no. 25-225-226).
The dialyzed homogenate was then concentrated by centrifugation at 2600 x g for 20 min to a volume of about 50 ml, rehomogenized, and then quick-frozen in 1-ml portions in individual 5-ml test tubes cooled in a dry ice-acetone bath. This simple enzyme homogenate has been successfully prepared 31 The mean apparent digoxin level found was 0.17 + 0.17 ng/ml (1 SD). Since that time, the assay has been performed using the 10-15 min incubation at 45-50°C and the procedure for storing ATP frozen as described above. Serum digoxin levels have been measured on eight more control patients. As shown in figure 5, the mean apparent digoxin level found was 0.0 ± 0.0 BROOKER, JELLIFFE ng/ml (1 SD), essentially the same as for the reagent blanks.
Precision
Serum from patients receiving digoxin therapy was pooled and then was divided into six identical specimens of 5 ml each for assay. Digoxin levels found were 2.5, 2.3, 2.6, 2.3, and 2.3 ng/ml. They averaged 2.4 ng/ml. The standard deviation was + 0.1 ng/ml, or + 4.2% of the mean. This degree of precision was also found at lower serum levels between 0.5 and 2 ng/ml, as shown in the data of recovery (fig.  4) . These findings suggest that the working analytical error (-+-2 SD) should be about +10%. Variance in nanograms per milliliter between each individual 50-Al TRIS aliquot assayed was 5% of the mean.
Noninterfering Drugs
In a further test of specificity, one pill or liquid specimen of each drug found in the medicine cabinet of the Clinical Research Center of the Los Angeles County-University of Southern California Medical Center was taken, and an entire pill or liquid specimen was subjected to assay for digoxin. Pills were hammered to a powder and taken up in 5 ml of 0.1M NaCl. Ampoules were brought to a volume of 5 ml wvith 0.1hI NaCl. The sample (including any undissolved material) xvas processed exactly as though it were a reagent blank, except that 100 Al of toluene and 650
Al of 100 mmv TRIS-HCl, pH 8.0, were used, rather than 20 Al and 130 du, respectively, following evaporation of the ether to dryness. As usual, however, duplicate 50-Al aliquots of TRIS were then subjected to assay for digoxin.
Thus one thirteenth of the 650 ,ul of TRIS was assayed for interference. If any evidence of interference from the entire specimen was found, another 50 ul of the same 650 ul of TRIS was diluted 1/10, 1/100, or 1/1,000 in 100 mm TRIS-HCl, pH 8.0, and reassayed. The results of this study of 130 drug preparations are shown in table 3. Only four drugs, diphenhydramine (Benadryl), PET (phenobarbital, ephedrine HCl, and theophylline), pentazocine (Talwin), and tripelennamine (Pyribenzaminie), required a 1/1.0(0 dilution to achieve a blanik result. Blank serum values were obtained in patien-ts receiving these drugs.
None of the steroid compounds assayed required dilutions beyond 1:100 to achieve a negative result. With regard to these, it has been suggested that maximal serum estradiol levels might occasionally be as high as 55 ng/ml in antepartum women,; well below the theoretical level of 770 ng/ml which here was found negative for digoxin. The .mlof8% mlof30% methanol in chloroform Figure 7 Separation of chlorofor m extracts of digitoxini, digoxin, and ouabaini otn a silica gel coluimn )repared as a chlloroform7i slurry inl a disposable Pasteur pipet. Samples were applied ini 3 nil of 2Sc miethaniol ini chloroforml. The columnirl was twashzed wvith 10 Twenty-four determinations of serum glycoside levels were made on nine patients receiving digitoxin without any clinical evidence of digitalis toxicity. As shown in figure  8 , serum glycoside levels ranged from 2.4 to 81.3 ng/ml, with a mean and a standard deviation of 31.8 ± 19.9 ng/ml, respectively.
Four determinations were made on four patients with digitalis toxicity which improved after treatment with digitoxin was stopped. Serum glycoside levels ranged from 38.2 to 62.7 ng/ml, with a mean and a standard deviation of 48.8 + 10.5 ng/ml, respectively.
In addition, two determinations of serum glycoside levels have been performed on two patients receiving gitalin (Gitaligin). One patient without evidence of digitalis toxicity had a serum glycoside level of 55.5 ng/ml, while the other patient, with evidence of digitalis toxicity, had 31.5 ng/ml. These results are consistent with the fact that the dominant glycoside in Gitaligin tablets has been shown to consist of material resembling digitoxin."
Patients Receiving Digoxin
Serum digoxin levels were measured in 83 nontoxic patients receiving digoxin. As shown in figure 8, serum glycoside levels ranged from 0.4 to 4.6 ng/ml, with a mean and a standard deviation of 1.43 + 0.76 ng/ml, respectively.
Twenty-one patients exhibited various toxic arrhythmias while on digoxin therapy. Serum glycoside levels in these patients ranged from 0.70 to 7.2 ng/ml (not shown), with a mean and a standard deviation of 3.1 + 0.8 ng/ml, a significantly higher level than that for the nontoxic patients (P < 0.001).
The 83 nontoxic patients and the 21 with arrhythmias were grouped together and ranked by their serum digoxin level ( fig. 9) . Of the 27 patients who had serum digoxin levels from 0 up to 1.0 ng/ml (mean, 0.8 ng/ml, only one, or 3.7Cc of this group, had an arrhythmia. Similarly, of 44 patients who had
Ci.c?uZation, Volumne XLV. Januar) 1972 serum levels from 1.0 to 2.0 ng/ml (mean, 1.4 ng/ml), only four, or 9.1% of the group, had arrhythmias. Seventeen patients had serum levels from 2.0 to 3.0 ng/ml (mean, 2.4 ng/ml), and two, or 11.8%, had arrhythmias.
In contrast, 11 patients had serum levels from 3.0 to 4.0 ng/ml (mean, 3.4 ng/ml), and all of them, or 100%, had arrhythmias. Finally, five patients had levels over 4 ng/ml (mean, 5.1 ng/ml), and three, or 60%, had arrhythmias. A probit analysis' of these findings was done, using a computer program in the Service Bureau Corporation's Call 360/Basic time-sharing computer system. 13 The resulting probit line, also shown in figure 9 . describes the general incidence of arrhythmias to be expected at any serum digoxin level on the basis of the above clinical data. At serum digoxin levels of 1.4 ng/ml, the average level found in patients without arrhythmias, there is a 10M risk of arrhythmias. At 2.0 ng/ml, the expected risk rises to 25%, while at 2.9 ng/ml it reaches 50%.
Discussion
The assay reported here is easy and rapid to set up and to put into operation. It Inicidenice of toxicity (arr1iythmia.s) fouind at various serum digoxin levels. It is interesting to compare the present assay with the immunoassay of serum digoxin by Smith and co-workers'4 } and Evered and associates. 16 The immunoassay appears to have at least a 10-fold specificity for digoxin over digitoxin. Because antibody response is variable froiii one animal to the next, 1 the specificity of this antibody may vary from lot to lot and thus requires careful standardization. In contrast, the present assay appears specific for digitalis compounds as a group, and the standard curve has remained remarkably constant from day to day, month to month, and from one glycoside to another.
Reported serum levels of digitalis leaf and digitoxin are 10 to 20 times higher than those of digoxin.'4-16 1t 11 Results with the present assay support these findings. Because of this, 5 ml of serum from patients on digitalis leaf, digitoxin, or Gitaligin goes off-scale with the present assay. We now ask the requesting physician which glycoside his patient is receiving, and assay only 1 ml of serum if the patient is said to be receiving digitalis leaf or digitoxin.
To date, six sera have been assayed for digoxin in which over 15 ng/ml of apparent digoxin were found. In the absence of evidence of digitalis toxicity, such very high levels strongly suggested that the patient might actually be receiving digitalis leaf or digitoxin. A check with the patients' physicians revealed that no evidence of digitalis toxicity was present. Further checking by their physicians then disclosed that all six patients actually had been receiving either digitalis leaf or digitoxin just prior to admission.
One patient subsequently found to be receiving digitoxin was further studied by using the disposable silica gel columni clhromatography, a step which separates dligitoxini digoxin, and ouabain from one another prior to assay. Only the digitoxin fraction contained assayable cardiac glycoside.
Published graphls'4 inidicate that, if the sera of these patients had been studied by immunoassay, results returned might have been in the range of 1.5 ng/ml or less of apparent digoxin, thus tending to preserve the false impression that the patients were receiving digoxin and were achieving normal or less than normal serum levels. In contrast, the present assay obtained results consistent with reported levels of digitalis leaf and digitoxin, and thus prompted further inquiry which disclosed and then confirmed the true situation. Without this assay, it is probable that these patients would have been unwittingly subjected to an unknowing replacement of common maintenance doses of digitalis leaf or digitoxin with common maintenance doses of digoxin. The results of such an unwitting replacement of a long-acting glycoside by a shorter-acting one, with its hazards of cumulation and of digitalis toxicity during the transition period, hax e been described." ' The assay reported here does not re(luire isotope counting procedure must be done by using appropriate standards prepared from the identified isotope in order to achieve a useful result. The simple extraction procedure used in the present assay, however, removes contaminating radioactivity present in serum of patients following a lung scan, even when as much as 10 FLCi of aggregated 1311 human albumin (Mallinckrodt) has been added to 1 ml of serum. Since the radioactivity present in serum of a patient should be much less than this after a dose of 100 to 300 tCi has been given for a lung scan, it is felt that the extraction procedure removes contaminating radioactivity present in serum following lung scans. In over 1,800 assays to date, no clinical problem has arisen with this assay on patients who have had lung scans.
Other Biologic Specimens
In addition, the extraction procedure is the feature of the present assay that makes it easily adaptable to assay of cardioactive glycosides in other biologic materials as well, and which may make this assay a rapid and easy general assay for active digitalis compounds in many types of biologic samples.
For example, a 47-year-old woman (G.R., PF# 301-89-78) was admitted to this center 3 hours after having ingested 100 0.1-mg digitoxin tablets. She had vomited once. Physical examination was unrevealing. An electrocardiogram revealed a sinus mechanism with a rate of 52/min. The P-R interval was 0.24 see. Serum was obtained for assay, urine collection was begun, and vigorous gastric lavage was instituted.
Serum digitoxin on admission was 51.0 ng/ml. In addition, assay of an aliquot of 4 liters of material obtained by gastric lavage revealed glycosides equivalent to 1.2 jtg/ml of digitoxin, suggesting that the gastric lavage had removed 4.8 of the 10 mg that had been Circulation, Volume XLV, January 1972 ingested. The results from both the serum and several samples prepared from gastric material were in the hands of ward personnel within 3 hours. Knowledge of the amount of glycoside removed by gastric lavage was most comforting to those caring for the patient.
It was thought that the patient might just have passed the stage where serum levels were highest. Since only mild A-V block was present, and since a large amount of digitoxin had been removed by gastric lavage, it was felt that she might subsequently do well without further intervention. She was carefully watched, and in fact recovered without further therapy. Subsequent daily serum digitoxin levels were 41.0, 31.6, and 24.4 ng/ml, while spot checks of two specimens of urine for digitoxin (extracting 0.5 ml of urine for assay) yielded digitoxin concentrations of 848 and 412 ng/ml on the 2 days after admission.
Six specimens of gastric contents and four of urine specimens from persons not receiving any digitalis, tested as controls, all gave negative results. The immunoassay has not been applied to assay of samples in gastric juice or urine.
Comparison to Other Assays
The present assay appears more rapid, sensitive, and precise than various mnodifications of the red blood cell-M"rubidium assay1' ' 23. 23 A similar large overlap in therapeutic and toxic serum glycoside levels was found for patients receiving digitalis leaf. The average therapeutic serum level was 27.8 ng/ml, quite close to that found for digitoxin. This would seem reasonable, as digitoxin is usually the dominant glycoside present in digitalis leaf.'" This is by no means universally true, howex er, as some varieties of digitalis purpurea leaf have been shown to contain very little digitoxin and much more gitoxin. Since digitalis leaf contains many active glycosides, each with its own individual pharmacokinetic properties and each with its own degree of binding to serum proteins, '4 an even greater overlap between therapeutic and toxic serum levels might be expected in patients receiving digitalis leaf.
Gitalin
Serum glycoside levels found in the two patients receiving Gitaligin were in the same general range as those found for patients receiving digitalis leaf or digitoxin. These results are consistent with the fact that Gitaligin is not a pure glycoside but is derived from an aqueous extract of digitalis purpurca." 38 Gitaligin tablets (0.5 mg) have been shown to contain 0.116 mg of material resembling digitoxin and 0.063 mg of material resembling gitoxin.1" These preliminary results for serum Gitaligin levels wxould suggest that therapy with one 0.5-mg Gitaligin tablet/day should yield serum glycoside levels roughlv similar to those found with 0.1 mg/dav of digitoxin.
Digoxin
In general, therapeutic serum levels of digoxin average 1.4 ng/ml. Levels founid in patients xvith various toxic arrhythmias average 3.1 ng/ml, suggesting that the ratio of toxic to therapeutic levels of digitoxin is 3.1:1.4, or 2.2:1, in close agreement xvith the clinical impression of 2:1. The amount of overlap found between therapeutic and toxic serum levels of digoxin is much less than that for the other glycosides studied, and the serum digoxin levels in patients with and without digoxin toxicity xvere significantlx different (P < 0.001). It is possible that the 10. Computed Body Stores (jig/kg) Figure 10 Correlation between computed total-body concentrationis of (ligoxin and t7easured seruim levels. The dashed litnes are the 9.5% confidence limits.
Circulation, VolZume XLV, January 1971 SERUM CARDIAC GLYCOSIDE ASSAY smaller overlap found may be due to the lesser binding of digoxin to serum proteins.3 A4 3 More meaningful data may thus be obtained for levels of serum digoxin than for the other glycosides.
The probit analysis of the incidence of arrhythmias found at various serum digoxin levels now permits a quantitative statement of the average risk of toxic arrhythmias occurring at any level of serum digoxin.
These data now permit the physician to select a risk of arrhythmias which he feels is reasonable for the urgency of his patient's clinical situation, and to try to achieve the serum digoxin level appropriate to that selected risk and body concentration using dosage regimens based on the documented kinetic properties of digoxin in patients with normal and reduced renal function.32 [39] [40] [41] Relationship of Serum Digoxin Levels to Digoxin Kinetics and to Dosage Regimens Serum digoxin levels in 70 additional patients were compared with total-body concentrations of digoxin calculated by a computer program which used only data on the patient's history of digoxin dosage, body weight, and renal function, and which is based upon mathematical descriptions of digoxin kinetics in man.') ' The results, shown in figure 10, reveal a highly significant correlation between the computed total-body concentrations of digoxin and measured serum digoxin levels (P <0.001). The dashed lines describe the 95% confidence limits for the solid regression line shown.
The data shown in figure 10 now verify the method of digoxin therapy described previously. 4 (0 For example, if a physician should now7 select a 10% risk of toxic arrhythmias for a euthyroid patient in normal electrolyte balance, without evidence of gastrointestinal malabsorption, who weighs 150 lb, a serum digoxin level of 1.4 ng/ml would be appropriate, as shown in figure 9 . As shown in figure  10 , this serum level is related to a computed total-body digoxin concentration of 10 ,g/kg, or approximately 0.5 mg/100 lb. The proper total oral loading dose to achieve this totalCirculation, Volunme XLV, January 1972 body concentration would therefore be approximately 0.75 mg, which could be given in two or three parts 6 hours apart to check the validity of the physician's therapeutic plan as described previously.4" If no evidence of toxicity is found with that loading dose, the subsequent proper daily maintenance dose to sustain this total-body glycoside concentration and serum digoxin level wNould then be 0.25 mg/day if creatinine clearance were 100 ml/min, 0.19 mg/day if it were 50 ml/min, or 0.11 mg/day if the patient were anuric.
In addition, the general relationships shown in figures 9 and 10 have been combined with the above concepts of dosage4" to form a nomogram for digoxin dosage as a small plastic card which physicians may carry in the wallet for bedside reference.42
